Contents of this document
Earnings presentation materialsFiscal year ended December 2025, full year8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥50,370 million+5.8%
Operating profit¥3,123 million+938.9%
Ordinary income¥2,366 million+447.7%
Net income¥-2,653 million
Full-year earnings forecast
Net Sales
¥52,000 million
Adjusted EBITDA
¥7,000 million
Operating profit
¥3,200 million
Ordinary income
¥2,800 million
Profit attributable to owners of the parentSpecific forecast figures not disclosed
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
売上高は業績予想値も超過、調整後EBITDA・営業利益は広告投資の拡大や賞与増加等により業績予想値は若干の未達Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- マレーシアJVのフル稼働Assumption10万KL×300円/L
- 直販の安定成長Assumption年率3%程度
- 微細藻類生産量Assumption2030年までに3倍程度
New initiatives
- バイオマスの5F戦略の本格展開
- 微細藻類のマルチ機能性素材・食品用途素材としての研究開発と国内BtoB販売強化
- 海外展開およびCKD領域での活用
- 飼料・肥料素材の機能性研究と拡販
- 藻油開発に向けた屋内タンク培養のスケールアップとコスト削減
- 2025年10月開始のウェルエイジングプラットフォーム『myme』
- 2026年1月5日付のジェファー液関連事業の譲受
- 20周年記念特別配当
Key KPIsA metric the company considers important as a management benchmark.
- Number of group direct-to-consumer subscription customers71 10,000 peopleYear on year against the same period last yearSlight increase
- Shareholders11 10,000 or more
- バイオ燃料供給実績130 Cases or more
- ユーグレナクッキー配布数2,000 万食以上
- CONC定期顧客数Year on year against the same period last yearup 41% year on year
- コラリッチ定期顧客数Year on year against the same period last year4%増
- プレミアムヘマチン定期顧客数Year on year against the same period last year22%増
Unit price and quantity metricsThese figures show sales broken down by price and volume.
顧客単価アップ、グループ直販定期顧客数71万人。数量・単価の具体的な数値分解は一部Not disclosedMedium-term management plan targets
Target fiscal yearFY2030
Net SalesApproximately ¥100 billion
Adjusted EBITDA160億円相当
Market Size / Share
- Food additives marketScale¥1 trillion or more
- 慢性腎臓病患者Scale約2,000万人
- 透析患者Scale約33万人
- CKD-related medical expensesScale年1.6兆円以上
Annual Dividend
Annual dividend per share2円の20周年記念特別配当
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Fiscal year ended December 2025, full year |
| Net Sales | ¥50,370 million (YoY +5.8%) |
| Operating profit | ¥3,123 million (YoY +938.9%) |
| Ordinary income | ¥2,366 million (YoY +447.7%) |
| Net income | ¥-2,653 million |
| Full-year earnings forecast | Net Sales ¥52,000 million / Adjusted EBITDA ¥7,000 million / Operating profit ¥3,200 million / Ordinary income ¥2,800 million / Profit attributable to owners of the parent Specific forecast figures not disclosed |
| Self-assessment against the plan | 売上高は業績予想値も超過、調整後EBITDA・営業利益は広告投資の拡大や賞与増加等により業績予想値は若干の未達 |
| Key KPIs | Indicator name Number of group direct-to-consumer subscription customers / Value 71 10,000 people / Year on year against the same period last year Slight increase, Indicator name Shareholders / Value 11 10,000 or more / Year on year against the same period last year Not disclosed, Indicator name バイオ燃料供給実績 / Value 130 Cases or more / Year on year against the same period last year Not disclosed, Indicator name ユーグレナクッキー配布数 / Value 2,000 万食以上 / Year on year against the same period last year Not disclosed, Indicator name CONC定期顧客数 / Value Not disclosed / Year on year against the same period last year up 41% year on year, Indicator name コラリッチ定期顧客数 / Value Not disclosed / Year on year against the same period last year 4%増, Indicator name プレミアムヘマチン定期顧客数 / Value Not disclosed / Year on year against the same period last year 22%増 |
| Unit price and quantity metrics | 顧客単価アップ、グループ直販定期顧客数71万人。数量・単価の具体的な数値分解は一部Not disclosed |
| Assumptions Underlying the Business Outlook | Item マレーシアJVのフル稼働 / Assumption 10万KL×300円/L, Item 直販の安定成長 / Assumption 年率3%程度, Item 微細藻類生産量 / Assumption 2030年までに3倍程度 |
| Medium-term management plan targets | Target fiscal year FY2030 / Net Sales Approximately ¥100 billion / Adjusted EBITDA 160億円相当 |
| Annual Dividend | Annual dividend per share 2円の20周年記念特別配当 / Interim and Year-End Breakdown Not disclosed |
| Market Size / Share | Market Food additives market / Scale ¥1 trillion or more, Market 慢性腎臓病患者 / Scale 約2,000万人, Market 透析患者 / Scale 約33万人, Market CKD-related medical expenses / Scale 年1.6兆円以上 |
| New initiatives | バイオマスの5F戦略の本格展開, 微細藻類のマルチ機能性素材・食品用途素材としての研究開発と国内BtoB販売強化, 海外展開およびCKD領域での活用, 飼料・肥料素材の機能性研究と拡販, 藻油開発に向けた屋内タンク培養のスケールアップとコスト削減, 2025年10月開始のウェルエイジングプラットフォーム『myme』, 2026年1月5日付のジェファー液関連事業の譲受, 20周年記念特別配当 |
Items this document does not state (16)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSegment resultsBreakdown of Factors Affecting the ChangeNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.